Our mission
- Antibodies being used as a T-cell targeting system
- Bispecific Kappa Lambda bodies
- CD47 blockade in action
- CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B‑cell lymphoma xenograft model. Xavier Chauchet, Laura Cons, et al.
- Edesa Biotech and Light Chain Bioscience Sign License Agreement
- Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
- Exclusive interview lead by PharmaBoardroom
- First Patient dosed with NILK-2401 in Phase I clinical trial
- First patient dosed with NILK-2301 in Phase I clinical trial
- First-in-human trial of NI-1801 in patients with solid cancers expressing mesothelin (MSLN)
- Light Chain Bioscience – A brand of Novimmune SA
- New publication in Cancer Immunology Research
- New publication in Frontiers
- New publication in MABS 2024
- Next-generation immunotherapy with native bispecific antibodies
- Swiss Biotech Award
